57278-42-9

Basic information

• Product Name: 8-METHYL-4-OXO-1,4-DIHYDRO-QUINOLINE-3-CARBOXYLIC ACID
• Synonyms: OTAVA-BB BB0107830100;SALOR-INT L149438-1EA;AURORA 17735;8-METHYL-4-OXO-1,4-DIHYDRO-QUINOLINE-3-CARBOXYLIC ACID
• CAS NO: 57278-42-9
• Molecular Formula: C11H9NO3
• Molecular Weight: 203.19
• Mol File: 57278-42-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 374.1 °C at 760 mmHg
• Flash Point: 180.1 °C
• Appearance: /
• Density: 1.367 g/cm³
• CAS DataBase Reference: 8-METHYL-4-OXO-1,4-DIHYDRO-QUINOLINE-3-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 8-METHYL-4-OXO-1,4-DIHYDRO-QUINOLINE-3-CARBOXYLIC ACID(57278-42-9)
• EPA Substance Registry System: 8-METHYL-4-OXO-1,4-DIHYDRO-QUINOLINE-3-CARBOXYLIC ACID(57278-42-9)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 57278-42-9(Hazardous Substances Data)

Usage

Description

8-METHYL-4-OXO-1,4-DIHYDRO-QUINOLINE-3-CARBOXYLIC ACID is a quinoline derivative with a molecular formula C12H11NO3, belonging to the family of carboxylic acids. It has potential applications in the pharmaceutical industry due to its structural similarity to some biologically active molecules.
Used in Pharmaceutical Industry:
8-METHYL-4-OXO-1,4-DIHYDRO-QUINOLINE-3-CARBOXYLIC ACID is used as a building block in the synthesis of various pharmaceutical drugs and agrochemicals, owing to its structural similarity to biologically active molecules.
Used in Drug Development and Research:
8-METHYL-4-OXO-1,4-DIHYDRO-QUINOLINE-3-CARBOXYLIC ACID is used as a potential candidate for drug development and research due to its potential antibacterial and antiviral properties.

Upstream product

• 95-53-4 o-toluidine 
• 19146-73-7 diethyl 2-((o-tolylamino)methylene)malonate 
• 77156-75-3 ethyl 1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylate 

Relevant articles and documents

Novel quinolone-3-carboxylic acid derivatives as anti-HIV-1 agents: design, synthesis, and biological activities

A new series of quinolone-3-carboxylic acids featuring different hydrophobic groups at N-1, C-2, C-7, and C-8 positions were synthesized and evaluated for their activity against single-cycle replicable HIV NL4-3 as inhibition rate of p24 expression in Hela cells cultures. Most of the synthesized compounds showed anti-HIV activity with no significant cytotoxicity at concentration of 100 μM. The most active compounds 4h, 4k, and 4j exhibited anti-HIV activity with an inhibition rate of 55, 71, and 84 %, respectively. A docking study using the crystallographic data available for PFV integrase including its complexes with Mg2+ and Raltegravir revealed that the active compounds could occupy same space near Raltegravir and interact with the Mg2+ ions in the active site. Thus, the anti-HIV activity of the synthesized compounds might involve a metal chelating mechanism. [InlineMediaObject not available: see fulltext.]

Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2

Due to the emerging role of protein kinase CK2 as a molecule that participates not only in the development of some cancers but also in viral infections and inflammatory failures, small organic inhibitors of CK2, besides application in scientific research, may have therapeutic significance. In this paper, we present a new class of CK2 inhibitors-3-carboxy-4(1H)-quinolones. This class of inhibitors has been selected via receptor-based virtual screening of the Otava compound library. It was revealed that the most active compounds, 5,6,8-trichloro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (7) (IC 50 = 0.3 μM) and 4-oxo-1,4-dihydrobenzo[h]quinoline-3-carboxylic acid (9) (IC50 = 1 μM), are ATP competitive (Ki values are 0.06 and 0.28 μM, respectively). Evaluation of the inhibitors on seven protein kinases shows considerable selectivity toward CK2. According to theoretical calculations and experimental data, a structural model describing the key features of 3-carboxy-4(1H)-quinolones responsible for tight binding to CK2 active site has been developed.